LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
Peaklamivudine; tenofovir disoproxil fumarate
NDAORALTABLET
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
A fixed-dose combination oral tablet containing lamivudine and tenofovir disoproxil fumarate, two nucleoside reverse transcriptase inhibitors (NRTIs) used in the treatment of HIV-1 infection. This combination is typically used as part of antiretroviral therapy regimens in treatment-experienced and treatment-naïve patients. The drugs work by inhibiting reverse transcriptase, blocking viral replication.
Peak
This product is at peak commercial maturity with moderate competitive pressure (30%), indicating stable demand and a mature brand team focused on optimization and retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This mature peak-lifecycle product offers stable career opportunities primarily in commercial execution, market access, and medical affairs rather than innovation or launch activities. Working on this asset provides exposure to HIV therapeutic expertise, managed care dynamics, and established patient support infrastructure.
Brand ManagerMedical Science Liaison
Worked on LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.